course

CATEGORY

Department of Dermatology

Department of Dermatology

Original Website

Staff

We provide medical care for patients with a wide range of skin diseases with good observation, deep consideration, and warm touch. We deal with all diseases that develop in the skin. Especially, we specialize in allergy, sweating disorders, autoimmune bullous disease, psoriasis, infectious diseases, skin surgery and skin tumors. We always see patients with skin diseases with consideration to the causes, mechanisms and goals. These attitudes drive us to explore skin biology and Dermatopathology.
In our department, many residents, who are dermatologists in training, receive practical training mainly in wards and outpatient clinics. We encourage residents to learn practical and clinical dermatology through the experiences of the actual cases. They acquire knowledge, technic, and problem-solving skills.

Research fields

We have investigated the correlation among sweating disturbance, barrier dysfunction of the skin, and inflammatory skin diseases, such as atopic and contact dermatitis.

  1. Mouse models of sweating disturbance associated with dry skin induced by cutaneous inoculation of herpes simplex virus.
  2. Basal sweating in the finger as an unrecognized machinery to maintain skin hydration: a possible therapeutic target to prevent hand eczema

We are investigating pathomechanisms that may trigger systemic inflammatory disease, including adverse drug reactions, autoimmune bullous disease and immune-related adverse reactions. According to our recent observations, neutrophil-to-lymphocyte ratio can be a good biomarker to predict the disease outcome in bullous pemphigoid, toxic epidermal necrolysis, generalized pustular psoriasis and herpes zoster.

  1. Drug cessation has a paradoxical effect on the outcome of drug-induced bullous pemphigoid (BP): Neutrophil-to-lymphocyte ratio (NLR) is a useful biomarker that can predict treatment benefits and outcomes in dipeptidyl peptidase 4 inhibitors-associated BP.
  2. Neutrophil-to-lymphocyte ratio change after starting therapy as a practical biomarker for predicting treatment benefit in patients with toxic epidermal necrolysis.